S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"We will NEVER sell out to China!" (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:HRMY

Harmony Biosciences - HRMY Stock Forecast, Price & News

$59.77
+2.33 (+4.06%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$57.50
$59.91
50-Day Range
$42.06
$59.94
52-Week Range
$31.54
$61.55
Volume
429,651 shs
Average Volume
467,535 shs
Market Capitalization
$3.55 billion
P/E Ratio
23.35
Dividend Yield
N/A
Price Target
$62.50

Harmony Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
4.6% Upside
$62.50 Price Target
Short Interest
Bearish
17.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of Harmony Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$33.20 M Sold Last Quarter
Proj. Earnings Growth
-7.41%
From $2.70 to $2.50 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

773rd out of 1,043 stocks

Pharmaceutical Preparations Industry

375th out of 510 stocks

HRMY stock logo

About Harmony Biosciences (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Stock News Headlines

Why Harmony Biosciences (HRMY) Stock Might be a Great Pick
Harmony Biosciences Recent Insider Activity
4 Analysts Have This to Say About Harmony Biosciences
Recap: Harmony Biosciences Q3 Earnings
What 5 Analyst Ratings Have To Say About Harmony Biosciences
Harmony Biosciences Could Soon Sing an Uplifting Tune
HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences: In Harmony
See More Headlines
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Company Calendar

Last Earnings
11/01/2022
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRMY
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.50
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$51.00
Forecasted Upside/Downside
+4.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$34.60 million
Pretax Margin
21.22%

Debt

Sales & Book Value

Annual Sales
$305.44 million
Cash Flow
$2.56 per share
Book Value
$5.80 per share

Miscellaneous

Free Float
38,735,000
Market Cap
$3.55 billion
Optionable
Not Optionable
Beta
0.52

Key Executives

  • Mr. Jeffrey S. Aronin (Age 54)
    Founder & Non-Exec. Chairman
    Comp: $85k
  • Mr. John Charles Jacobs M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $885.55k
  • Mr. Sandip S. Kapadia CPA (Age 52)
    M.B.A., Exec. VP & CFO
    Comp: $717.03k
  • Dr. Jeffrey M. Dayno M.D.Dr. Jeffrey M. Dayno M.D. (Age 65)
    Exec. VP & Chief Medical Officer
    Comp: $702.74k
  • Mr. Jeffrey  Dierks M.B.A.Mr. Jeffrey Dierks M.B.A. (Age 50)
    Exec. VP & Chief Commercial Officer
    Comp: $613.88k
  • Mr. Andrew Serafin J.D. (Age 47)
    M.B.A., Exec. VP & Chief Strategy Officer
    Comp: $570.92k
  • Mr. David Bradshaw
    Head of Technical Operations
  • Ms. Sharon Goldbach
    Head of Facilities Operations & Exec. Admin.
  • Luis Sanay
    Head of Investor Relations
  • Mr. Christian Ulrich
    Gen. Counsel













HRMY Stock - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRMY shares.
View HRMY analyst ratings
or view top-rated stocks.

What is Harmony Biosciences' stock price forecast for 2023?

8 brokers have issued 12 month price objectives for Harmony Biosciences' shares. Their HRMY share price forecasts range from $51.00 to $70.00. On average, they expect the company's share price to reach $62.50 in the next year. This suggests a possible upside of 4.6% from the stock's current price.
View analysts price targets for HRMY
or view top-rated stocks among Wall Street analysts.

How have HRMY shares performed in 2022?

Harmony Biosciences' stock was trading at $42.64 at the beginning of 2022. Since then, HRMY stock has increased by 40.2% and is now trading at $59.77.
View the best growth stocks for 2022 here
.

When is Harmony Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our HRMY earnings forecast
.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its quarterly earnings results on Tuesday, November, 1st. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.85. The business earned $117.21 million during the quarter, compared to analyst estimates of $113.11 million. Harmony Biosciences had a trailing twelve-month return on equity of 62.83% and a net margin of 38.84%.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

(HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

What is Harmony Biosciences' stock symbol?

Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.10%), Vivo Capital LLC (5.73%), Vanguard Group Inc. (5.06%), State Street Corp (1.82%), Macquarie Group Ltd. (1.11%) and Bellevue Group AG (1.11%). Insiders that own company stock include Andreas Wicki, Holdings A/S Novo, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends
.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harmony Biosciences' stock price today?

One share of HRMY stock can currently be purchased for approximately $59.77.

How much money does Harmony Biosciences make?

Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $3.55 billion and generates $305.44 million in revenue each year. The company earns $34.60 million in net income (profit) each year or $2.56 on an earnings per share basis.

How many employees does Harmony Biosciences have?

The company employs 180 workers across the globe.

How can I contact Harmony Biosciences?

Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com.

This page (NASDAQ:HRMY) was last updated on 12/1/2022 by MarketBeat.com Staff